These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2870650)

  • 21. Tardive dyskinesia in chronic schizophrenic inpatients.
    Kua EH; Ang PC; Siew HC
    Singapore Med J; 1982 Feb; 23(1):19-21. PubMed ID: 6126008
    [No Abstract]   [Full Text] [Related]  

  • 22. [Neuroleptics and extrapyramidal effects from the biochemical viewpoint. Discussion by the Workshop on Neuroleptics and the Extrapyramidal System].
    Seyfried C
    Arzneimittelforschung; 1978; 28(9):1537-8. PubMed ID: 38815
    [No Abstract]   [Full Text] [Related]  

  • 23. Use of novel antipsychotic drugs.
    Raleigh F
    Pharmacotherapy; 1996; 16(6 Pt 2):160S-165S; discussion 166S-168S. PubMed ID: 8948000
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anticholinergic use in hospitalised schizophrenic patients in Belgium.
    De Hert M; Wampers M; van Winkel R; Peuskens J
    Psychiatry Res; 2007 Aug; 152(2-3):165-72. PubMed ID: 17445906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness.
    Honer WG; Kopala LC; Rabinowitz J
    J Psychopharmacol; 2005 May; 19(3):277-85. PubMed ID: 15888513
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recognition and management of acute neuroleptic-induced extrapyramidal motor and mental syndromes.
    Dose M
    Pharmacopsychiatry; 2000 Sep; 33 Suppl 1():3-13. PubMed ID: 11072761
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A discriminant validity study of negative symptoms with a special focus on depression and antipsychotic medication.
    Lewine RR
    Am J Psychiatry; 1990 Nov; 147(11):1463-6. PubMed ID: 1977328
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia.
    Canuso CM; Dirks B; Carothers J; Kosik-Gonzalez C; Bossie CA; Zhu Y; Damaraju CV; Kalali AH; Mahmoud R
    Am J Psychiatry; 2009 Jun; 166(6):691-701. PubMed ID: 19411369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.
    Morrato EH; Dodd S; Oderda G; Haxby DG; Allen R; Valuck RJ
    Clin Ther; 2007 Jan; 29(1):183-95. PubMed ID: 17379060
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes.
    Correll CU
    J Am Acad Child Adolesc Psychiatry; 2008 Jan; 47(1):9-20. PubMed ID: 18174821
    [No Abstract]   [Full Text] [Related]  

  • 31. Use or abuse of antiparkinsonian drugs by psychiatric patients.
    Saran AS
    J Clin Psychiatry; 1986 Mar; 47(3):130-2. PubMed ID: 2869028
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The pharmacist in the care of ambulatory mental health patients.
    Ivey MF
    Am J Hosp Pharm; 1973 Jul; 30(7):599-602. PubMed ID: 4715103
    [No Abstract]   [Full Text] [Related]  

  • 33. A comparison of antipsychotic drug-defined daily doses versus chlorpromazine equivalent doses in patients with or without extrapyramidal motor symptoms.
    Barr AM; Honer WG; Johnson JL; Wu TK; Procyshyn RM
    J Clin Psychopharmacol; 2010 Dec; 30(6):741-3. PubMed ID: 21057241
    [No Abstract]   [Full Text] [Related]  

  • 34. The rabbit syndrome and antiparkinsonian medication in schizophrenic patients.
    Wada Y; Yamaguchi N
    Neuropsychobiology; 1992; 25(3):149-52. PubMed ID: 1357583
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Depot neuroleptic therapy: an underutilized treatment option.
    Glazer WM; Kane JM
    J Clin Psychiatry; 1992 Dec; 53(12):426-33. PubMed ID: 1362569
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antipsychotic treatment and extrapyramidal symptoms amongst schizophrenic inpatients.
    Høiberg MP; Nielsen B
    Nord J Psychiatry; 2006; 60(3):207-12. PubMed ID: 16720511
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Meige's syndrome associated with risperidone therapy.
    Ananth J; Burgoyne K; Aquino S
    Am J Psychiatry; 2000 Jan; 157(1):149. PubMed ID: 10618045
    [No Abstract]   [Full Text] [Related]  

  • 38. Advantages and disadvantages of depot-neuroleptics as maintenance medication for chronic schizophrenics.
    Möller HJ; Kissling W
    Clin Neuropharmacol; 1986; 9 Suppl 4():259-62. PubMed ID: 2882841
    [No Abstract]   [Full Text] [Related]  

  • 39. [Schizophrenia: adverse effects of atypical neuroleptics].
    Bettina Polk B
    Med Monatsschr Pharm; 2003 Feb; 26(2):57-9. PubMed ID: 12619525
    [No Abstract]   [Full Text] [Related]  

  • 40. Extrapyramidal side effects: a historical perspective.
    Rifkin A
    J Clin Psychiatry; 1987 Sep; 48 Suppl():3-6. PubMed ID: 2887555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.